Overview
- Saturday’s World Parkinson’s Day reporting highlighted forecasts from Spanish neurologists that cases could rise from more than 12 million today to about 25.2 million by 2050, driven mainly by population ageing with added risks from genetics and pesticide exposure.
- In Spain, the neurological society says more than 200,000 people live with Parkinson’s and the patient count has doubled since 2012, with typical diagnosis delays of one to three years that leave symptoms harder to manage.
- Peru’s health ministry reports that nearly 8 in 10 people with certified Parkinson-related disability are classified as severe, while local experts say late diagnoses and scarce specialists outside Lima push patients to advanced stages.
- Treatment pipelines are widening beyond symptom relief, with a phase‑3 trial of a drug that targets alpha‑synuclein proteins and a conditional approval in Japan for a stem‑cell therapy, though no cure exists yet.
- Coverage in Mexico points to higher‑risk regions like Sinaloa and Colima linked to chemical exposure, and clinicians stress early non‑motor clues—loss of smell, REM sleep disturbance, constipation, mood changes—plus tailored rehab and family support to preserve daily function.